1Roth JA, Swisher SG, Meyn RE, et al. p53 tumor suppressor gene therapy for cancer. Oncology, 1999, 13: 148-154.
2Chang EH, Pirollo KF, Bouker KB, et al. p53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today, 2000,6:358-364.
3Sasaki R, Shirakawa T, Zhang ZJ, et al. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys, 2001, 51:1336-1345.
4Swisher SG, Roth JA. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am, 2002,11:521-535.
5Lawler J, Miao WM, Duquette M, et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol, 2001,159: 1949 - 1956.
6Frank DK, Frederick MJ, Liu TJ, et al. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res, 1998, 4:2521-2528.
7Introgen′s Advexin therapy halts tumor growth in advanced esophageal cancer patients. Introgen Therapeutics, Inc. News Release, 2003-06-02.
8D′Orazi G, Marchetti A, Crescenzi M, et al. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J Gene Med, 2000, 2: 11-21.
9Buller RE, Runnebaum IB, Karlan BY, et al. A Phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther, 2002, 9:553-566.
10Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther, 2002, 9:979-986.
